logo-loader

Arecor progresses with insulin candidate clinical trial

Published: 11:26 04 Oct 2019 BST

Arecor - Arecor progresses with insulin candidate clinical trial
The private pharmaceutical firm expects preliminary results by the end of the year

Arecor Limited has completed the dosing and all patient visits in phase I of its ultra-rapid acting insulin candidate, AT247.

The private pharmaceutical firm, which conducted the trial in Austria, said it expects preliminary results by the end of the year.

WATCH: Arecor doses first patient in Phase I trial for ultra-rapid acting insulin product

The product is designed to improve treatment for people living with Type I diabetes, by accelerating insulin absorption to manage more effectively blood glucose levels, especially after meals.

“The completion of the AT247 Phase I clinical trial is an important step in our strategy to develop even faster-acting insulins targeted at improving treatment and healthcare outcomes for people living with Type I diabetes,” said chief executive Sarah Howell.

“I look forward to reporting the headline data from this Phase I study in due course, the first product in our proprietary development pipeline.”

Arecor Therapeutics announces collaboration on oral GLP-1 drug for diabetes...

Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell joined Proactive's Stephen Gunnion with details of a collaboration with TRX Biosciences to develop an oral GLP-1 product for treating type 2 diabetes and obesity. GLP-1s are therapeutic peptides known for improving blood sugar levels and...

2 weeks, 1 day ago